Purpose Current standard chemotherapeutic regimens for malignant melanoma are unsatisfactory. Although in vitro studies of arsenic trioxide (ATO) have demonstrated promise against melanoma, recent phase II clinical trials have failed to show any signiWcant clinical beneWt when used as a single agent. To enhance the eYcacy of ATO in the treatment of melanoma, we sought to identify compounds that potentiate the cytotoxic eVects of ATO in melanoma cells. Through a screen of 2,000 marketed drugs and naturally occurring compounds, a variety of antibiotic inhibitors of mitochondrial protein translation were identiWed. Methods The mechanism of action for the most eVective agent identiWed, thiostrepton, was examined in a panel of melanoma cells. EVects of combinatorial ATO and thiostrepton treatment on cytotoxicity, apoptosis, mitochondrial protein content, and reactive oxygen species (ROS) were assessed. Results Thiostrepton (1 M) sensitized three out of Wve melanoma cell lines to ATO-mediated growth inhibition. Treatment with thiostrepton resulted in reduced levels of the mitochondrial-encoded protein cytochrome oxidase I (COX1). Exposure to thiostrepton in combination with ATO resulted in increased levels of cleaved poly (ADPribose) polymerase and cellular ROS. The growth inhibitory and pro-apototic eVects of addition of the ATO/thiostrepton combination were reversed by the free radical scavenger N-acetyl-l-cysteine. Conculsions Our data suggest that thiostrepton enhances the cytotoxic eVects of ATO through a ROS-dependent mechanism. Co-administration of oxidative stress-inducing drugs such as thiostrepton in order to enhance the eYcacy of ATO in the treatment of melanoma warrants further investigation.
Introduction
The incidence of melanoma is increasing at an alarming rate [11] . Furthermore, metastatic melanoma has a poor prognosis, with a median survival of 6 months [7] . Current chemotherapeutic regimens for malignant melanoma provide limited clinical beneWt with response rates ranging from 10-20% and fail to improve patient survival [24] . The need for new eVective therapies in the treatment of metastatic melanoma is clear.
Arsenic trioxide (ATO) is an anti-cancer agent whose use originated in traditional Chinese medicine. More recently, the discovery of its profound eYcacy in acute promyelocytic leukemia (APL) has renewed interest in ATO as an antineoplastic agent [6, 25] . Clinical studies have demonstrated the utility of ATO in other hematologic malignancies including multiple myeloma [3] and myelodysplastic syndrome [20] . ATO has also shown promise in the treatment of solid tumors including neuroblastoma, head and neck cancer, gastric cancer, prostate and ovarian cancers, and renal cell carcinoma [1, 12, 23, 27, 30] . While in vitro studies reportedly demonstrated ATO-mediated induction of apoptosis in a variety of melanoma cell lines [13] , ATO showed only modest activity in patients with metastatic melanoma when administered as a single agent [17, 26] .
In the present study we sought to identify therapeutic agents that augment the cytotoxic eVects of ATO on melanoma. Through a screen of 2,000 marketed drugs and naturally occurring compounds and subsequent mechanism-based testing, we have identiWed a group of antibiotics including tetracyclines and thiostrepton that signiWcantly enhance ATO-mediated growth inhibition and apoptosis in melanoma cells. Our results reveal that these agents-which inhibit eukaryotic mitochondrial translation-sensitize melanoma cells to ATO through a mechanism dependent upon the induction of reactive oxygen species (ROS).
Materials and methods

Reagents
ATO, meclocycline, minocycline, thiostrepton, chloramphenicol, fusidic acid, and N-acetyl-l-cysteine (NAC) were purchased from Sigma-Aldrich (St. Louis, MO).
Cell lines M-14, SK-Mel-19, SK-Mel-94, SK-Mel-173, and Yusac2 cells were maintained in Dulbecco's modiWed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillinstreptomycin [5] . All cells were cultured at 37°C in a 10% CO 2 humidiWed atmosphere.
Chemical library screening
The Spectrum library (Microsource Discovery Systems, Gaylordsville, CT), containing 2,000 marketed drugs and naturally occurring compounds, was used to screen eVects on SK-Mel-19 cells. Cells were seeded at a density of 50,000 cells/cm 2 in 96-well plates and allowed to adhere overnight. Library compounds were added to cell cultures at a Wnal concentration of 1 M, either alone or in combination with 1 M ATO. After a 72 h incubation period, cellular proliferation was measured using the CellTiter 96 ® AQueous non-radioactive cell proliferation assay (Promega, Madison, WI), according to manufacturer's instructions. Absorbances were measured using a microplate reader (Biorad model 550) at 495 nm. The absorbance of control wells exposed to vehicle alone deWned 100% viability and the eVect of drugs on cellular proliferation was expressed as a percentage of cell viability relative to untreated cells.
Apoptosis assay
Cells were treated with 1 M ATO, 1 M thiostrepton, or both for 18 h. Cells were harvested and cellular lysate was obtained from lysis buVer. Thirty microgram of total protein was heat denatured and resolved on 10% SDS-PAGE gels. Following protein transfer to PVDF membrane, samples were probed with primary antibodies to poly (ADP-ribose) polymerase (PARP) and cleaved PARP (rabbit polyclonal, Cell Signaling Technology, Boston, MA). Following wash cycles, membranes were probed with secondary donkey anti-rabbit IgG (Amersham, Piscataway, NJ). Immunoreactive bands were visualized using ECL detection reagent (PerkinElmer, Waltham, MA) and X-OMAT processing. Densitometry values were calculated using ImageQuant TL software.
Mitochondrial translation assay
Cells were incubated with 1 M thiostrepton for 0, 6, 12, 18, 24, or 48 h. Protein was harvested and western blotting was performed as described above, using primary antibody against COXI (mouse monoclonal, Santa Cruz Biotechnologies, Santa Cruz, CA) and secondary goat anti-mouse IgG (Accurate Chemical and ScientiWc Corporation, Westbury, NY).
Measurement of intracellular ROS generation
Intracellular ROS generation was directly visualized by Xuorescent microscopic examination of cells following staining with the oxidant-sensitive probe H 2 DCFDA. Cells were incubated with indicated compound(s) for 18 h. Intracellular ROS levels were determined using Image-iT TM LIVE green reactive oxygen species detection kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. DNA was counterstained with Hoechst 33342. Cells were examined under microscopy using Xuorescein Wlter sets (Zeiss Axiophot upright phase contrast).
Results
Tetracyclines and thiostrepton enhance ATO-mediated growth inhibition
We found that a number of melanoma cell lines demonstrated substantial resistance to the cytotoxic eVects of ATO (data not shown). In order to screen for agents that sensitize otherwise-resistant melanoma cells to ATO, we chose highly ATO-resistant SK-Mel-19 melanoma cells, in which the IC 50 for growth inhibition by ATO is 4-7 M, and moderately ATO-resistant M-14 melanoma cells, which display an IC 50 of approximately 2 M (Fig. 1) . We screened the commercially available Spectrum Collection in SK-Mel-19 cells in the presence and absence of 1 M ATO, a clinically achievable concentration that is minimally growth inhibitory to the cells in vitro. We sought compounds that lacked growth inhibitory eVect when used alone, but which showed a greater than 30% increase in growth inhibition when combined with 1 M ATO.
Several tetracycline derivatives were found to sensitize SK-Mel-19 and M-14 melanoma cells to the growth inhibitory eVects of ATO. As shown in Fig. 1 , meclocycline and minocycline signiWcantly inhibit cellular proliferation when combined with ATO, compared to either agent alone, in both SK-Mel-19 and M-14 melanoma cells. Because previous studies showed that the antiproliferative eVects of tetracyclines in certain mammalian cells results from binding to, and inhibition of, mitochondrial ribosomes [28] , we hypothesized that the sensitization to ATO was due to inhibition of mammalian mitochondrial protein synthesis by the tetracyclines [18] .
To test this hypothesis, a literature search was performed to identify other inhibitors of mitochondrial protein synthesis structurally unrelated to tetracyclines. Thiostrepton is reported to be a potent inhibitor of both the mitochondrial and prokaryotic ribosome [31] . We found that thiostrepton at 1 M, a concentration previously shown to inhibit mitochondrial protein translation [31] , strongly enhanced ATOmediated inhibition of cellular proliferation in SK-Mel-19 and M-14 cells, despite minimal growth inhibition as a single agent (Fig. 1) . Furthermore, a range of thiostrepton concentrations enhanced the growth inhibitory eVects of 1uM ATO (Fig. 1 ). The addition of 1 M thiostrepton resulted in a 50% or greater decrease in ATO IC 50 for three out of Wve melanoma cell lines tested (Table 1) .
We also tested a number of antibiotics described in the literature as less potent inhibitors of mitochondrial protein translation when compared to tetracyclines or thiostrepton. Neither chloramphenicol [18] nor fusidic acid [31] sensitized melanoma cells to ATO-induced inhibition of cellular proliferation when administered at a concentration of 1 M (data not shown).
ATO in combination with thiostrepton enhances apoptosis
Because combination treatment resulted in reduced cellular proliferation, we evaluated the induction of apoptosis in treated cells via assessment of poly-ADP ribose polymerase (PARP) cleavage. Cleavage of full length PARP protein (116 kDa) into a stable fragment (85 kDa) is an important cellular marker of apoptosis [16] . As shown in Fig. 2 , signiWcantly higher levels of cleaved PARP protein were present in M-14 melanoma cells exposed to the combination of ATO/thiostrepton than with either agent alone, indicating enhanced levels of apoptosis. The addition of ATO or Thiostrepton decreases the level of COXI in M-14 cells
To examine whether thiostrepton inhibits mitochondrial protein translation in melanoma cell lines, levels of COXI were assessed. The cytochrome c oxidase I gene (COXI) is encoded in the mitochondrial genome, and the mRNA product subsequently translated by mitochondrial ribosomes. Incubation of M-14 cells with thiostrepton resulted in a time-dependent decrease in COXI protein levels (Fig. 3) . A noticeable decrease in COXI protein levels is evident by 18 h. These results are consistent with inhibition of mitochondrial protein translation by thiostrepton in melanoma cells.
Thiostrepton enhances the cytotoxic eVects of ATO through a ROS dependent mechanism
Mitochondrial dysfunction and perturbations in mitochondrial gene expression have been associated with enhanced production of ROS [4] . Furthermore, cytotoxic eVects of ATO on tumor cells has been postulated to occur through activation of ROS and modulation of glutathione redox systems [8] . This led us to investigate the role of ROS in thiostrepton-mediated enhancement of ATO toxicity in melanoma cells. We hypothesized that the combination of ATO and a mitochondrial protein translation inhibitor would increase intracellular ROS levels. To evaluate the role of ROS in ATO/thiostrepton cytotoxicity, we used the oxidant sensitive probe carboxy-H 2 DCFDA. Carboxy-H 2 DCFDA enters live cells where esterases deacetylate the molecule. In the presence of ROS, the reduced Xuorescein compound is oxidized and emits a bright green Xuorescent signal. The ATO/thiostrepton combination resulted in signiWcantly higher levels of intracellular ROS compared to treatment with either drug alone (Fig. 4) , suggesting that the combined eVect of ATO/thiostrepton is mediated by ROS.
To further demonstrate the involvement of ROS in ATO/ thiostrepton cytotoxicity, we repeated cellular proliferation and apoptosis assays with the addition of the free radical scavenger, N-acetyl-l-cysteine (NAC). At a concentration of 100 M, NAC reversed ATO/thiostrepton-induced growth inhibition and restored levels of cleaved PARP to those observed in untreated cells (Fig. 5) . Taken together, these data suggest that the cytotoxic eVects of ATO/ thiostrepton on melanoma cells are mediated by oxidative stress.
Discussion
The eYcacy of ATO in the treatment of APL as well as evidence supporting the promise of this agent in the treatment of other solid and hematological tumors prompted clinical trials evaluating the utility of ATO in the treatment of metastatic melanoma [17, 26] . These studies revealed only modest eVects of ATO when administered as a single agent, although it was noted that treatment was well-tolerated. Studies that involve co-administration of ATO with other agents in order to enhance its eYcacy in the treatment of metastatic melanoma are reportedly in progress [2] .
The highly eVective antitumor action of ATO in APL occurs at low concentrations of drug (less than 0.5 M) [21] . In contrast, most studies of solid tumor cells require strikingly higher doses in order to induce substantial apoptosis or growth inhibition. However, the incidence of ATOmediated side eVects makes the administration of the higher doses needed to achieve these levels clinically impractical. Although not speciWcally discussed in reports on the clinical trials of ATO in metastatic melanoma, the relative lack of sensitivity of melanoma cell lines in vitro suggests that the modest eVect observed in clinical trials may be due in large part to dosing limitations. In order to overcome this clinical limitation, we sought to identify agents that sensitize Fig. 3 Thiostrepton decreases the level of COXI in M-14 cells in a time-dependent manner. Cells were incubated with 1 M thiostrepton for multiple time periods (0-48 h) followed by western blotting for COXI (38 kDa). An untreated sample was used as a negative control. Afterwards, the membrane was stripped and reprobed with anti--actin antibody (45 kDa) as a loading control melanoma cells to ATO, thereby potentially allowing for the enhancement of antitumor eVects to be achieved in patients without raising the concentration of ATO administered to toxic levels. In this study, treatment of melanoma cells with the antibiotic thiostrepton in combination with ATO resulted in robust growth inhibition at low concentrations of ATO that are readily achievable in patients (Fig. 1) .
We have found that thiostrepton-mediated sensitization of melanoma cells to ATO occurs through a ROS dependent mechanism. Thiostrepton inhibits eukaryotic mitochondrial protein translation (Fig. 3) . SpeciWcally, thiostrepton inhibits both prokaryotic and mammalian mitochondrial ribosomes through binding to the large ribosomal subunit, thereby inhibiting the translocation step of protein translation [19, 22] . Although it has been well documented that mitochondrial dysfunction results in altered ROS production, a recent report by Bonawitz et al. [4] demonstrates that defective mitochondrial gene expression leads to increased ROS production in eukaryotes. This correlation led us to investigate the role of ROS in thiostrepton-mediated enhancement of ATO cytotoxicity. We demonstrate that combinatorial treatment of melanoma cells with ATO and thiostrepton results in a signiWcant increase in intracellular ROS levels as compared to treatment with either agent alone (Fig. 4) . Furthermore, the growth inhibitory eVects of ATO/thiostrepton treatment are reversed when melanoma cells are also treated with the free radical scavenger NAC (Fig. 5) . These data support the notion that increased ROS production (possibly resulting from impaired mitochondrial translation) contributes to thiostrepton-mediated enhancement of ATO cytotoxicity in melanoma.
Multiple cellular actions of ATO have been described, including eVects on cellular signaling and alteration of cellular redox systems. Evidence from studies on a range of malignancies has shown that ATO-induced apoptosis is determined in part by intracellular redox status. For example, the susceptibility of various leukemic cell lines to ATO-induced growth inhibition and apoptosis is inversely correlated with glutathione (GSH) content [8] . Furthermore, experimental modulation of GSH content can alter the cellular response to ATO. Increasing the GSH content with NAC or lipoic acid rendered leukemic cells more resistant to the cytotoxic eVects of ATO [8] . Arsenicresistant NB4 cell clones demonstrated susceptibility to ATO when GSH levels were depleted with L-buthionine-(S,R)-sulfoximine (BSO) [9] . In another study, pretreatment with selenite, which increases the activity of glutathione peroxidase (GPx) and therefore lowers H 2 O 2 , rendered APL cells resistant to otherwise toxic levels of ATO [15] . Similar data exists for solid tumors as well. BSO enhanced ATO-induced apoptosis in renal cell carcinoma [29] and formation of free radicals by the antioxidant trolox enhanced ATO-mediated oxidative stress in breast cancer cells [10] . Previous research in our laboratory has shown that redox status is also important in determining melanoma cell response to ATO. BSO sensitized various melanoma cell lines to ATO-induced growth inhibition and apoptosis (unpublished data). The data suggesting that redox status is an important determinant of the cellular response to ATO have led to a number of clinical trials exploring this relationship. For example, ascorbic acidthought to auto-oxidize in the cell, decreasing the cellular pool of GSH-has shown beneWcial eVects when administered with ATO to patients with multiple myeloma [3] . Indeed, two of the Wve melanoma cell lines examined in the current study did not show thiostrepton-mediated sensitization to ATO. Characterization of the redox status of thiostrepton-responsive versus non-responsive melanoma cell lines might provide further insight into the role of ROS in ATO sensitization.
In the present study, we demonstrate that thiostrepton sensitizes melanoma cells to ATO cytotoxicity through an ROS dependent mechanism. Thiostrepton is commercially available as part of a topical antibiotic mixture used to treat bacterial infections in animals and has also been used to eVectively treat murine bacterial systemic infections [14] . However, to date, it has not been approved for human use. The data presented here warrant further characterization of ATO sensitization by thiostrepton through in vivo studies in order to assess the possible clinical eVectiveness of this drug combination in the treatment of metastatic melanoma. Additionally, toxicology studies in animal models will be performed to determine the safest and most beneWcial mode of human administration. Other antibiotic inhibitors of mitochondrial protein translation addressed in this study including minocycline may serve as a better candidate for further in vivo study and clinical development given its extensive history of safe use in man as well as oral availability.
While eYcacy of ATO against melanoma cells can be demonstrated in vitro, there has been diYculty in translating these results to the clinic. Combination therapy is a potential method to increase the eYcacy of ATO in melanoma. Consistent with data from studies of other malignancies, our research suggests that increasing oxidative stress in melanoma cells by inhibition of mitochondrial protein translation sensitizes them to ATO. In future trials of ATO in metastatic melanoma, co-administration of a drug that increases oxidative stress, either by inhibition of mitochondrial protein translation or by some other means, may increase the eYcacy of this promising and well-tolerated agent. 
